Novartis Close To EU Approval For Zolgensma At Last
SMA Drug Backed by CHMP
Executive Summary
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
You may also be interested in...
Novartis Digital Strategy Dampens COVID-19 Impact
The Swiss major says operations have not faced significant disruptions from the coronavirus pandemic but recruitment of patients for new trials, including a high-profile trial of inclisiran, have been impacted.
Novartis's Gene Therapy Zolgensma Has Durable Effects At Five Years
AveXis/Novartis’s one-time AAV9 vector-based intravenous gene therapy for spinal muscular atrophy, Zolgensma, continues to have beneficial effects up to five years after its administration to babies, and an intrathecal formulation has significant promise in older infants.
Eyes On Pricing As Zolgensma Moves Closer To Japan Market
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.